On Apr. 30, 2012, Hologic announced the acquisition of San Diego-based Gen-Probe, a molecular diagnostics company, for $3.7 billion, or $82.75 a share. The price represented a 20 percent premium over Gen-Probe’s previous Friday closing value of $68.71.

The deal combined Gen-Probe’s leading diagnostics for sexually transmitted diseases and its blood screening business with Hologic’s global market presence and distribution primarily targeting women’s health.